OS Therapies Inc. has announced the formation of a new subsidiary, OS Animal Health, Inc., to commercialize OST-HER2 for the treatment of canine osteosarcoma. This strategic move aims to capitalize on the substantial market opportunity in veterinary oncology, with the canine osteosarcoma market valued at approximately $1.35 billion. OS Animal Health will operate independently from OS Therapies, with separate funding and a focus on re-establishing USDA conditional approval for OST-HER2, targeting submission in the latter half of 2025. This development follows recent positive clinical data and a new patent protecting the commercial manufacturing process for OST-HER2, securing its platform until 2040.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.